Kovack Advisors Inc. Trims Stock Position in Thermo Fisher Scientific Inc. $TMO

Kovack Advisors Inc. decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,299 shares of the medical research company’s stock after selling 149 shares during the quarter. Kovack Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $527,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Nuveen LLC bought a new position in Thermo Fisher Scientific in the 1st quarter worth $532,360,000. EdgePoint Investment Group Inc. bought a new position in shares of Thermo Fisher Scientific in the first quarter worth about $172,139,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Thermo Fisher Scientific by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock valued at $1,368,859,000 after buying an additional 329,974 shares in the last quarter. Auto Owners Insurance Co increased its holdings in Thermo Fisher Scientific by 6,773.5% in the 1st quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company’s stock worth $143,309,000 after acquiring an additional 283,810 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in Thermo Fisher Scientific by 18.3% during the 1st quarter. Alliancebernstein L.P. now owns 1,766,067 shares of the medical research company’s stock worth $878,795,000 after acquiring an additional 272,747 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 17,104 shares of the business’s stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at $65,247,057.48. The trade was a 13.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the completion of the sale, the executive vice president directly owned 21,152 shares of the company’s stock, valued at $12,144,420.80. The trade was a 1.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 54,420 shares of company stock worth $28,134,684. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TMO. Citigroup increased their price objective on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the stock a “neutral” rating in a research note on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. Hsbc Global Res cut Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Argus boosted their price target on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Robert W. Baird lifted their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. Nineteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $601.65.

Thermo Fisher Scientific Stock Up 2.2%

Shares of TMO opened at $568.25 on Friday. The business’s 50 day simple moving average is $510.86 and its 200-day simple moving average is $457.75. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The stock has a market capitalization of $214.58 billion, a price-to-earnings ratio of 32.83, a price-to-earnings-growth ratio of 3.27 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the previous year, the business posted $5.28 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.